MCID: MLT113
MIFTS: 51

Multicentric Castleman Disease

Categories: Rare diseases, Immune diseases

Aliases & Classifications for Multicentric Castleman Disease

MalaCards integrated aliases for Multicentric Castleman Disease:

Name: Multicentric Castleman Disease 12 53
Plasmablastic Multicentric Castleman Disease 12 53
Multicentric Giant Lymph Node Hyperplasia 12 53
Multi-Centric Castleman's Disease 44 73
Pmcd 12 53
Mcd 12 53
Multicentric Plasma Cell Variant of Castleman's Disease 53
Idiopathic Multicentric Castleman's Disease 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0111152
ICD10 33 D36.0
MeSH 44 C537372
UMLS 73 C1334815

Summaries for Multicentric Castleman Disease

NIH Rare Diseases : 53 Multicentric Castleman disease (MCD) is a rare condition that affects the lymph nodes and related tissues. It is a form of Castleman disease that is "systemic" and affects multiple sets of lymph nodes and other tissues throughout the body (as opposed to unicentric Castleman disease which has more "localized" effects). The signs and symptoms of MCD are often nonspecific and blamed on other, more common conditions. They can vary but may include fever; weight loss; fatigue; night sweats; enlarged lymph nodes; nausea and vomiting; and an enlarged liver or spleen. The exact underlying cause is unknown. Treatment may involve immunotherapy, chemotherapy, corticosteroid medications and/or anti-viral drugs.

MalaCards based summary : Multicentric Castleman Disease, also known as plasmablastic multicentric castleman disease, is related to castleman disease and pneumonia, and has symptoms including fever An important gene associated with Multicentric Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Ganciclovir and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and spleen, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A Castleman disease characterized by systemic inflammatory symptoms, polyclonal lymphoproliferation, cytopenias, and multiple organ system dysfunction caused by a cytokine storm often including interleukin-6.

Related Diseases for Multicentric Castleman Disease

Diseases related to Multicentric Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 castleman disease 33.5 CRP IL6 KRT15
2 pneumonia 30.2 CRP IL10 IL5 IL6
3 hematopoietic stem cell transplantation 30.2 IFNG IL10 IL6
4 lymphoma, non-hodgkin, familial 29.1 ABCB1 BCL6 IGH PAX5
5 systemic lupus erythematosus 28.9 CRP F3 IFNG IL10 IL6
6 kaposi sarcoma 12.0
7 malonyl-coa decarboxylase deficiency 11.8
8 macular dystrophy, corneal 11.8
9 multiple carboxylase deficiency 11.8
10 metaphyseal chondrodysplasia, schmid type 11.7
11 human herpesvirus 8 11.5
12 unicentric castleman disease 11.2
13 cold agglutinin disease 10.9 CRP IL6
14 cryopyrin-associated periodic syndrome 10.9 CRP IL6
15 eye lymphoma 10.9 IL10 IL6
16 angioimmunoblastic lymphadenopathy with dysproteinemia 10.9 IL5 IL6
17 bagassosis 10.8 IL5 IL6
18 cardiogenic shock 10.8 CRP IL6
19 acute transverse myelitis 10.8 IL10 IL6
20 acute cholangitis 10.8 CRP IL6
21 neutrophilia, hereditary 10.8 CRP IL6
22 uremic pruritus 10.8 CRP IL6
23 chronic meningitis 10.7 CRP IL5
24 acute pyelonephritis 10.7 CRP IL10 IL6
25 funisitis 10.7 IL10 IL6
26 hemorrhagic fever with renal syndrome 10.7 CRP IL10 IL6
27 leptospirosis 10.7 CRP IL10 IL6
28 pyelonephritis 10.7 CRP IL10 IL6
29 appendicitis 10.7 CRP IL10 IL6
30 spinal disease 10.7 CRP IL6
31 mesenteric lymphadenitis 10.7 CRP IL5 IL6
32 bacterial meningitis 10.7 CRP IL10 IL6
33 endocarditis 10.7 CRP IL10 IL6
34 radiculopathy 10.7 IL10 IL5 IL6
35 peritonitis 10.6 CRP IL10 IL6
36 kawasaki disease 10.6 CRP IL10 IL6
37 cow milk allergy 10.6 IL10 IL5
38 acute pancreatitis 10.6 CRP IL10 IL6
39 blue toe syndrome 10.6 CRP F3
40 acquired hemophilia a 10.6 F3 F8
41 fournier gangrene 10.6 F3 F8
42 angina pectoris 10.6 CRP F3 IL6
43 nodular lymphocyte predominant hodgkin lymphoma 10.6 BCL6 PAX5
44 acquired hemophilia 10.6 F3 F8
45 intermediate coronary syndrome 10.6 CRP F3 IL6
46 eosinophilic fasciitis 10.6 IFNG IL5
47 hyperlucent lung 10.5 IFNG IL10
48 scrub typhus 10.5 CRP F3 IL10
49 thrombocytosis 10.5 CRP F3 IL6
50 b-cell growth factor 10.5 IFNG IL6

Graphical network of the top 20 diseases related to Multicentric Castleman Disease:



Diseases related to Multicentric Castleman Disease

Symptoms & Phenotypes for Multicentric Castleman Disease

UMLS symptoms related to Multicentric Castleman Disease:


fever

MGI Mouse Phenotypes related to Multicentric Castleman Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.14 F3 IL6 F8 IL21 ID1 ABCB1
2 homeostasis/metabolism MP:0005376 10.11 IL5 IL10 F3 F8 IL6 IL21
3 immune system MP:0005387 10.1 IL6 F8 IL21 ID1 ABCB1 PAX5
4 cardiovascular system MP:0005385 10.06 F3 IL10 IL6 ID1 ABCB1 BCL6
5 digestive/alimentary MP:0005381 9.98 IL5 IL10 IL6 ID1 KRT15 ABCB1
6 liver/biliary system MP:0005370 9.8 IL10 IL6 ID1 ABCB1 BCL6 IFNG
7 neoplasm MP:0002006 9.7 F3 IL6 ID1 PAX5 IFNG IL5
8 reproductive system MP:0005389 9.56 IL5 IL10 F8 IL6 ID1 ABCB1
9 respiratory system MP:0005388 9.17 IL5 IL10 F3 IL6 ID1 BCL6

Drugs & Therapeutics for Multicentric Castleman Disease

Drugs for Multicentric Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
2
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
3 Anti-Infective Agents Phase 4,Phase 2,Phase 1
4 Antiviral Agents Phase 4,Phase 2
5 Ganciclovir triphosphate Phase 4,Phase 2
6 Siltuximab Approved, Investigational Phase 2,Phase 1,Early Phase 1 541502-14-1
7
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
9
Zidovudine Approved Phase 2 30516-87-1 35370
10
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
11
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
12
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
13
Everolimus Approved Phase 2 159351-69-6 6442177
14
Lenograstim Approved, Investigational Phase 2 135968-09-1
15
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
16
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
17
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
18
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
19 Pomalidomide Approved Phase 1, Phase 2 19171-19-8
20
Doxil Approved June 1999 Phase 2,Phase 1 31703
21 Analgesics Phase 2
22 Antibodies Phase 2,Phase 1,Early Phase 1
23 Antibodies, Monoclonal Phase 2,Phase 1,Early Phase 1
24 Antipyretics Phase 2
25 Histamine Antagonists Phase 2
26 Histamine H1 Antagonists Phase 2
27 Immunoglobulins Phase 2,Phase 1,Early Phase 1
28 Pharmaceutical Solutions Phase 2
29 Alkylating Agents Phase 2,Phase 1
30 Angiogenesis Inhibitors Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 2,Phase 1
32 Anti-Bacterial Agents Phase 2,Phase 1
33 Anti-Inflammatory Agents Phase 2,Phase 1
34 Antineoplastic Agents, Alkylating Phase 2,Phase 1
35 Antineoplastic Agents, Hormonal Phase 2,Phase 1
36 Antirheumatic Agents Phase 2,Phase 1
37 glucocorticoids Phase 2,Phase 1
38 Hormone Antagonists Phase 2,Phase 1
39 Hormones Phase 2,Phase 1
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
41 Immunosuppressive Agents Phase 2,Phase 1
42 Anti-HIV Agents Phase 2
43 Antimetabolites Phase 2
44 Anti-Retroviral Agents Phase 2
45 Nucleic Acid Synthesis Inhibitors Phase 2
46 Reverse Transcriptase Inhibitors Phase 2
47 Adjuvants, Immunologic Phase 2
48 Antibiotics, Antitubercular Phase 2,Phase 1
49 Antifungal Agents Phase 2
50 Antimitotic Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
2 A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Completed NCT01024036 Phase 2 Siltuximab;Placebo;Best Supportive Care (BSC)
3 A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Completed NCT01400503 Phase 2 Siltuximab
4 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
5 TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03043105 Phase 2 Thalidomide, cyclophosphamide and prednisone
6 Tocilizumab for KSHV-Associated Multicentric Castleman Disease Recruiting NCT01441063 Phase 2 Zidovudine;Tocilizumab;Valganciclovir (VGC)
7 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Recruiting NCT00092222 Phase 2 Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
8 Siltuximab in Schizophrenia Recruiting NCT02796859 Phase 1, Phase 2 Siltuximab;normal saline
9 Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy Terminated NCT00127569 Phase 2 Rituximab
10 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
11 A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment Completed NCT01183598 Phase 1 tocilizumab [RoActemra/Actemra]
12 Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma Recruiting NCT02659930 Phase 1 liposomal doxorubicin;pomalidomide
13 Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Terminated NCT02109224 Phase 1 Ibrutinib
14 Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Completed NCT00695422
15 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
16 Unlock the Cell: Castleman's Disease Flow Cytometry Study Recruiting NCT02853968
17 Castleman Disease Collaborative Network Biobank Recruiting NCT02871050
18 International Registry for Patients With Castleman Disease Recruiting NCT02817997
19 Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Withdrawn NCT02805868 Early Phase 1

Search NIH Clinical Center for Multicentric Castleman Disease

Cochrane evidence based reviews: multi-centric castleman's disease

Genetic Tests for Multicentric Castleman Disease

Anatomical Context for Multicentric Castleman Disease

MalaCards organs/tissues related to Multicentric Castleman Disease:

41
Lymph Node, Liver, Spleen, B Cells, Bone, Bone Marrow, T Cells

Publications for Multicentric Castleman Disease

Articles related to Multicentric Castleman Disease:

(show top 50) (show all 153)
# Title Authors Year
1
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. ( 29732477 )
2018
2
The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. ( 29684500 )
2018
3
Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. ( 29157621 )
2018
4
Plasma Cell Variant Multicentric Castleman Disease and Kaposi's Sarcoma in a Treatment-Naive HIV-Infected Patient. ( 29345958 )
2018
5
Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. ( 29675946 )
2018
6
Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease. ( 29607228 )
2018
7
Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case reporta8c. ( 29701172 )
2018
8
Late-onset skin involvement on the forehead in multicentric Castleman disease. ( 28244070 )
2017
9
Multicentric Castleman disease: consensus at last? ( 28336727 )
2017
10
EBV+ HHV-8+ Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV+ Man: An Evolving Clinicopathologic Entity. ( 29198143 )
2017
11
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. ( 28087540 )
2017
12
TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. ( 28135567 )
2017
13
Corrigendum: Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. ( 28845155 )
2017
14
Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report. ( 28501028 )
2017
15
Thin-section Computed Tomographic Findings of Multicentric Castleman Disease Changing Over 10 Years. ( 28914746 )
2017
16
Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. ( 28143881 )
2017
17
(18)F-FDG PET/CT in multicentric Castleman disease: a case report. ( 26904580 )
2016
18
A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination. ( 26948831 )
2016
19
Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. ( 26980221 )
2016
20
TAFRO syndrome: An atypical variant of KSHV-negative multicentric Castleman disease. ( 26663467 )
2016
21
Atypical presentation of multicentric Castleman disease in a pediatric patient: pleural and pericardial effusion. ( 26614115 )
2016
22
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. ( 26634298 )
2016
23
Human Herpesvirus Type 8-positive Multicentric Castleman Disease. ( 27133959 )
2016
24
Multicentric Castleman disease: Where are we now? ( 27296355 )
2016
25
Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease. ( 27221364 )
2016
26
Unicentric versus Multicentric Castleman Disease. ( 27618317 )
2016
27
Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease: Two Case Reports. ( 26598921 )
2016
28
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. ( 26805758 )
2016
29
Case report and literature review: Glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric castleman disease. ( 27741115 )
2016
30
Bone marrow manifestations in multicentric Castleman disease. ( 26817834 )
2016
31
iNKT and memory B cells alterations in HHV-8 multicentric Castleman disease. ( 28060720 )
2016
32
Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome. ( 25093377 )
2015
33
Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy. ( 25900626 )
2015
34
Budd-Chiari syndrome, a rare complication of multicentric Castleman disease: A case report. ( 26137030 )
2015
35
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. ( 26124203 )
2015
36
Siltuximab for Multicentric Castleman Disease-Letter. ( 26473194 )
2015
37
18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters. ( 25828248 )
2015
38
FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. ( 25601959 )
2015
39
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. ( 26327301 )
2015
40
Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi. ( 26242311 )
2015
41
Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. ( 25208471 )
2015
42
Leukemic phase of a large B-cell lymphoma arising in KSHV-associated multicentric Castleman disease. ( 26756053 )
2015
43
Tocilizumab for AA Amyloidosis after Treatment of Multicentric Castleman Disease with Steroids, Chemotherapy and Rituximab for Over 20 Years. ( 26666616 )
2015
44
KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies. ( 24771491 )
2015
45
(Multicentric Castleman Disease with Monoclonal Incomplete IgH Restriction: A Rare Coexistence). ( 26490523 )
2015
46
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease. ( 26394632 )
2015
47
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. ( 24387011 )
2014
48
Multicentric Castleman disease presenting with fever. ( 25282064 )
2014
49
Successful single-lung transplantation for multicentric Castleman disease. ( 25193223 )
2014
50
Siltuximab for multicentric Castleman disease. ( 25110138 )
2014

Variations for Multicentric Castleman Disease

Expression for Multicentric Castleman Disease

Search GEO for disease gene expression data for Multicentric Castleman Disease.

Pathways for Multicentric Castleman Disease

Pathways related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 BCL6 CCL4 IFNG IL10 IL5 IL6
2
Show member pathways
12.65 ABCB1 IFNG IL10 IL21 IL5 IL6
3 12.43 BCL6 IFNG IL10 PAX5
4
Show member pathways
12.36 IFNG IL10 IL21 IL5 IL6
5
Show member pathways
12.29 IFNG IL10 IL5 IL6
6
Show member pathways
12.12 IFNG IL10 IL21 IL6
7
Show member pathways
11.98 IFNG IL10 IL21 IL5 IL6
8
Show member pathways
11.96 BCL6 IL10 IL6
9
Show member pathways
11.91 CCL4 IFNG IL10 IL5 IL6
10 11.86 BCL6 IL10 IL6
11 11.77 IFNG IL10 IL6
12 11.72 CCL4 IFNG IL6
13 11.72 IFNG IL10 IL21 IL6
14 11.69 IFNG IL5 IL6
15 11.69 IFNG IL10 IL5 IL6
16 11.67 IFNG IL10 IL5
17 11.62 IFNG IL10 IL6
18 11.54 BCL6 IL10 IL5
19 11.53 CCL4 IL5 IL6
20 11.4 CCL4 IL10 IL6
21 11.39 IFNG IL10 IL6
22 11.35 IFNG IL10 IL5
23 11.18 IFNG IL10 IL6
24 11.09 IFNG IL5 IL6
25 10.98 BCL6 IL10 IL21 PAX5
26 10.91 CRP IL6
27 10.85 IFNG IL10 IL5
28 10.83 ID1 PAX5
29 10.4 IFNG IL10 IL5 IL6

GO Terms for Multicentric Castleman Disease

Cellular components related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CCL4 CRP F3 F8 IFNG IL10
2 extracellular space GO:0005615 9.28 CCL4 CRP F3 F8 IFNG IL10

Biological processes related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.83 CRP ID1 IFNG IL6
2 immune response GO:0006955 9.73 CCL4 IFNG IL10 IL21 IL5 IL6
3 positive regulation of DNA binding transcription factor activity GO:0051091 9.69 IL10 IL5 IL6
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 IFNG IL21 IL6
5 regulation of signaling receptor activity GO:0010469 9.63 CCL4 IFNG IL10 IL21 IL5 IL6
6 humoral immune response GO:0006959 9.58 IFNG IL6 PAX5
7 positive regulation of B cell proliferation GO:0030890 9.54 BCL6 IL21 IL5
8 acute-phase response GO:0006953 9.5 CRP F8 IL6
9 positive regulation of immunoglobulin secretion GO:0051024 9.49 IL5 IL6
10 negative regulation of lipid storage GO:0010888 9.48 CRP IL6
11 type 2 immune response GO:0042092 9.43 BCL6 IL10
12 inflammatory response GO:0006954 9.43 BCL6 CCL4 CRP IL10 IL5 IL6
13 cytokine-mediated signaling pathway GO:0019221 9.1 BCL6 CCL4 F3 IL10 IL5 IL6

Molecular functions related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CCL4 IFNG IL10 IL21 IL5 IL6

Sources for Multicentric Castleman Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....